Article of the day, September 1st, suggested by the Immune Oncology Research Institute

Immune Oncology Research Institute shared a post on LinkedIn:

“Article of the day! Suggest by the Immune Oncology Research Institute.

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma

Authors: Christian U. Blank, Minke W. Lucas, Richard A. Scolyer, Bart A. van de Wiel, Alexander M. Menzies, Marta Lopez-Yurda, Lotte L. Hoeijmakers, Georgina V. Long et al.

Author Affiliations: The Netherlands Cancer Institute, Amsterdam UMC, Leiden University Medical Center, Erasmus MC, Utrecht University, Medisch Centrum Leeuwarden, Medisch Spectrum Twente, Máxima MC, NSW Health Pathology, Royal North Shore Hospital, Peter MacCallum Cancer Centre, Calvary Mater Newcastle, Maria Sklodowska-Curie National Research Institute of Oncology , et al.

Source: Immune Oncology Research Institute/LinkedIn

Immune Oncology Research Institute (IMMONC), established in 2022, is a non-profit, independent, patient-centered research institute. The mission of IMMONC is to advance the cancer knowledge and care through breakthrough scientific research, to integrate innovative immune-oncology therapies into the clinical practice for different types of cancers, to generate and collect clinical data for the identification of new therapeutic targets, developing predictive models and optimizing patient outcomes, to increase the availability and accessibility of those discoveries for the cancer patients, to create a world-class professional environment, to attract the brightest minds in cancer field and to train the next generation researchers.

Other posts featuring Immune Oncology Research Institute on OncoDaily.